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during the second year
of monthly doses of oral
vitamin D3.
• Reduction in rates was
similar with high-dose
(100 000 IU/mo) and
standard-dose (12 000
IU/mo) treatment.
In sickle cell disease, respiratory infection and asthmamay lead to respiratory complications
that are a leading cause of morbidity and mortality. Vitamin D has anti-infective and
immunomodulatory effects thatmaydecrease the risk for respiratory infections, asthma, and
acute chest syndrome. We conducted a randomized double-blind active-controlled clinical
trial to determinewhethermonthly oral vitaminD3 can reduce the rate of respiratory events
in childrenwith sickle cell disease. Seventy sickle cell subjects, ages 3-20 years, with baseline
records of respiratory events over 1 year before randomization, underwent screening.
Sixty-two subjects with 25-hydroxyvitamin D levels of 5-60 ng/mL were randomly assigned
to oral vitamin D3 (100 000 IU or 12 000 IU, n5 31 each) under observed administration once
monthly for 2 years. The primary outcome was the annual rate of respiratory events
(respiratory infection, asthma exacerbation, or acute chest syndrome) ascertained by the
use of a validated questionnaire administered biweekly. Analysis included 62 children
(mean age of 9.9 years, 52% female, and predominantly with homozygous HbS disease
[87%]) with mean baseline 25-hydroxyvitamin D of 14.3 ng/mL. The annual rates of
respiratory events at baseline and intervention years 1 and 2 were 4.34 6 0.35, 4.28 6
0.36, and 1.49 6 0.37 (high dose) and 3.91 6 0.35, 3.34 6 0.37, and 1.54 6 0.37 (standard
dose), respectively. In pediatric patients with sickle cell disease, 2-year monthly oral vitamin
D3 was associated with a.50% reduction in the rate of respiratory illness during the second
year (P 5 .0005), with similar decreases associated with high- and standard-dose treatment.
This trial was registered at www.clinicaltrials.gov as #NCT01443728.
Introduction
Acute respiratory illness is a principal cause of morbidity and mortality worldwide1 and can be
devastating for children with sickle cell disease, an inherited red blood cell disorder affecting an
estimated 100 000 Americans,2 predominantly of African ancestry. Sickle cell disease is characterized
by a shortened life expectancy, hemolytic anemia, acute episodes of vaso-occlusive pain, and recurrent
chronic damage to vital organs.2,3 Pulmonary manifestations are common and often severe. Respiratory
infections or asthma attacks that would have no lasting effects in individuals with no sickle
hemoglobinopathy can trigger severe or even fatal manifestations in those with sickle cell disease.4
For instance, children with influenza and sickle cell disease are hospitalized at a rate that is .50-fold
Submitted 6 November 2017; accepted 6 April 2018. DOI 10.1182/
bloodadvances.2017013979.
The full-text version of this article contains a data supplement.
© 2018 by The American Society of Hematology
8 MAY 2018 x VOLUME 2, NUMBER 9 969
greater than children without sickle cell disease.5 Asthma is
common, affecting 15-28% of children with sickling disorders.6
Unique to sickle cell disease is a respiratory complication that is
characterized by fever, respiratory symptoms, and a new pulmonary
infiltrate, known as acute chest syndrome (ACS).7 Commonly
precipitated by respiratory infections and asthma, ACS is the leading
cause of death in sickle cell disease.6,7 The pathogenesis of sickle cell
lung disease is unclear but involves microvascular occlusion,
hemolysis-induced endothelial dysfunction, and vasculopathy that
produce a chronic inflammatory state, often exacerbated by an
infectious trigger.2,8,9 Compromised immunity from functional asplenia
may contribute to the risks for respiratory infections and pulmonary
disease.10 Improved vaccination and penicillin prophylaxis have greatly
reduced the risk of bacterial pathogens but are ineffective against
viruses and atypical organisms that now predominate as risks for
ACS.11
Vitamin D, in addition to its role in calcium and bone homeostasis,
is a multifunctional regulator of innate and adaptive immune
responses and of inflammation.12-16 Vitamin D acts, in part, through
its metabolite 1,25-dihydroxyvitamin D [1,25(OH)2D],
17,18 which
binds to the vitamin D receptor to function as a transcription factor,
inducing vitamin D–responsive genes that are present in most, if not
all, cells of the immune system.19 1,25(OH)2D mediates the innate
immune host response against respiratory tract pathogens by
stimulating expression of cathelicidin (hCAP18/LL37), an antimi-
crobial peptide with activity against viral, bacterial, and fungal
pathogens.20,21 It also regulates the adaptive immune system by
modulating T-lymphocyte proliferation and function and by down-
regulating the inflammatory response and cytokine expression.22 In
addition to these functions of 1,25(OH)2D, the parent compound
vitamin D itself is a potent and general mediator of endothelial
stability and barrier function.23 A recent Cochrane review of
randomized clinical trials identified high-quality evidence that vitamin
D supplementation reduced the risk for asthma exacerbations,
although too few pediatric trials were included to permit definitive
conclusions for children.24,25 Although observational studies have
consistently found significant associations between low vitamin D
levels and increased susceptibility to respiratory infections,
randomized clinical trials examining the effects of vitamin D
supplementation on the risk for respiratory infections have had
conflicting findings that are due, in part, to differences in the
baseline status of the participants, the duration of the studies, and
the amount and frequency of dosing.26-29
Children with sickle cell disease are at high risk for vitamin D
deficiency due to limited sun exposure, dark skin color, and poor
nutrition. Our own and other observational studies have found that
most children with sickle cell disease have low vitamin D status.30,31
Contrary to an earlier hypothesis,32 the low levels of vitamin D in
black Americans are not explained by differences in the concen-
tration of vitamin D–binding protein.33,34 Considering that individ-
uals with low vitamin D levels seem to derive the most benefit from
supplementation29 and that children with sickle cell disease have a
heightened susceptibility to respiratory infections and asthma,
together with a greatly increased vulnerability to complications,
we conducted a 2-year active-controlled double-blind randomized
clinical trial comparing monthly high-dose oral vitamin D3 (100 000
IU, daily equivalent 3333 IU/d) with standard-dose oral vitamin D3
(12 000 IU, daily equivalent 400 IU/d)35 to determine whether oral
vitamin D3 (cholecalciferol) can reduce the risk for respiratory
complications in children and adolescents, 3-20 years old, with
sickle cell disease (ViDAS trial). Because of the established risks for
inadequate mineralization of the skeleton associated with vitamin D




Prior to the clinical trial, we prospectively collected baseline data of
respiratory events, including respiratory infections, asthma exacer-
bations, and ACS, ascertained by the use of a respiratory events
questionnaire (see supplemental Methods for a copy of the
questionnaire). Participants were 99 children with sickle cell
disease, ages 2-19 years, recruited from among ;200 patients
followed at the Columbia University Medical Center Pediatric Sickle
Cell Program.
Participants in the clinical trial were recruited from among these 99
eligible patients, ages 3-20 years old, with baseline respiratory
events data collected over an approximate period of 1 year prior to
the trial that served as baseline for the primary outcomemeasure of the
randomized trial. Subjects were to have been on a stable dose of
hydroxyurea or chronic asthma medication for $3 months, not on
chronic transfusion therapy, not on chronic steroids (except for inhaled
steroids) or anticonvulsants, no diagnosis of rickets, and without history
of hypercalcemia or diagnosis of any medical condition associated with
hypercalcemia. The protocol was approved by the Institutional Review
Board of Columbia University Medical Center and by the US Food and
Drug Administration (IND Number 107584). Written informed consent
was provided by participants, parents, and guardians, along with
written informed assent when applicable. Participants received
reimbursement for travel expenses.
Trial design
This study was a double-blind active-controlled parallel-group trial
with random assignment in a 1:1 ratio to receive treatment once
monthly for 24 months under observation with vitamin D3 (100 000
or 12 000 IU) in identical capsules (Tishcon Laboratories Inc.,
Salisbury, MD). An overview of the trial design is shown in Figure 1.
Participants with screening 25–hydroxyvitamin D (OHD) ,5 ng/mL
were not randomized but were eligible to participate in an open-label
manner. These patients were evaluated by a pediatric endocrinol-
ogist (I.F.) and treated with oral vitamin D3: 100 000 IU every other
week for 2 months and then 100 000 IU monthly thereafter for the
duration of the study. Patients with 25-OHD .60 ng/mL were also
excluded; none of the participants had levels .60 ng/mL. Using
computer-generated randomization, participants with 25-OHD
concentrations of 5-60 ng/mL were randomly assigned using
randomly permuted blocks of size 2, 4, or 6 assignments, with
separate schema prepared for stratification by age (3-9 and 10-20
years), gender, and hydroxyurea therapy. Randomization was
performed by the research pharmacy; all other research staff and
participants were blinded to allocation. Participants were seen
monthly for observed administration of study medication and interval
history, including respiratory events, dietary vitamin D and calcium
intake (Block Calcium/Vitamin D Screener; NutritionQuest, Berkeley,
CA), sunlight exposure, and adverse events. Serum albumin–
corrected calcium and spot urinary calcium/creatinine ratios were
performed monthly for the first 6 months, every other month for the
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following 6 months, and every 3 months for the second year.
Blood specimens for 25-OHD, obtained immediately before study
drug administration, were collected at the same intervals, stored at
2112°F (280°C), and analyzed in a single batch at the end of the
study using ultra-performance liquid chromatography–tandemmass
spectrometry. A Clinical Trial Data and Safety Monitoring Board
consisting of a Chair, a biostatistician, a pediatric hematologist, and
a pediatric endocrinologist was organized to monitor the trial.
Outcome measures
The primary outcome was the annual rate of respiratory events,
defined as episodes of respiratory infections, asthma exacerbations,
or ACS, ascertained by the use of a validated questionnaire38
administered in person during monthly outpatient study visits and
biweekly telephone interviews and confirmed by review of clinical
records from outpatient visits and hospitalizations. The Respiratory
Questionnaire had a sensitivity of 83% and a specificity of 77% in
identifying the presence of 9 viral respiratory pathogens: adenovirus
(B, C, and E), bocavirus, coronavirus (229E, NL63, and OC43),
enterovirus, influenza virus (A and B), metapneumovirus, para-
influenza virus (1, 2, 3, 4a, and 4b), rhinovirus, and respiratory
syncytial virus (A and B).38 The questionnaire queried whether the
subject has had any of the following 6 symptoms in the past 2
weeks: difficulty breathing, wheezing, fever, cough, runny nose, and
sore throat. If a symptom(s) was present, additional questions were
asked about duration and severity of symptom(s), medication use,
visit to a medical provider, hospitalization, and missed school day(s)
due to the illness. A “respiratory event” was considered when $1
of the 6 symptoms occurred, except for fever alone without
accompanying respiratory symptoms or a runny nose accompanied
by itchy/watery eyes suggestive of allergy. A new event was
counted if $7 days had elapsed since the last counted event.
Patients with prolonged respiratory symptom(s) lasting .2 weeks
were evaluated by the study pulmonologist (M.K.), whose final
diagnosis determined whether the symptom(s) represented a
respiratory event. All questionnaires were reviewed and adjudicated
in a blinded fashion by a principal investigator (M.T.L.) to determine
whether a respiratory event had occurred. A “respiratory infection”
was defined as (1) runny nose, cough, or sore throat for$2 days or
any of these symptoms for $1 day accompanied by fever, not
otherwise attributed to allergy; (2) physician-diagnosed pharyngitis,
otitis media, or influenza; or (3) physician-diagnosed croup,
bronchiolitis, or pneumonia. An “asthma exacerbation” was defined
as a physician-diagnosed acute asthma that required treatment with
corticosteroids, emergency room treatment, or hospital admission.
A standard definition was used for ACS as an acute illness
characterized by fever and/or respiratory symptoms, accompanied
by a new pulmonary infiltrate on a chest radiograph.39 In instances
in which there was an overlap of these diagnoses within a single
duration of symptoms, such as when respiratory infection preceded
an asthma exacerbation or ACS or when infection or acute asthma
occurred with an ACS, the separate diagnoses were counted as a
single event. For secondary outcomes, pulmonary function tests
(spirometry, lung volumes, and diffusion capacity) and fractional
exhaled NO (FENO) were measured at baseline and at 12 and
24 months. Grip strength was measured by hand-held dynamom-
etry at baseline and every 6 months for 24months. Other prespecified
secondary outcome measures included immune and bone turnover
markers, which will be reported elsewhere.
Statistical methods
Our primary study analysis was an examination of the annual rate of
respiratory events (infections, asthma exacerbations, or ACS) in
comparison with the rate of respiratory events over a baseline
period of 1 year, using an intention-to-treat analysis. The study
sample size estimation, using the conditional efficient score
method,40 and the statistical analysis plan are detailed in the
supplemental Methods. The original sample size of 40 participants
Patients with baseline respiratory events data
Screening
Outcome measures (Year 1 & Year 2 assessments)
Primary: Respiratory events (infection, asthma, ACS)
Secondary: PFT, FENO, muscle strength, immune & bone markers






Oral Vitamin D3 100,000 IU
per month for 24 months
Oral Vitamin D3 12,000 IU




Figure 1. ViDAS trial schema. FENO, fractional exhaled NO; PFT,
pulmonary function tests.
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per group was estimated to provide power$0.9 with a 2-sided a of
0.05, using an effect size of a 40% reduction in respiratory events
with allowance for 15% loss to follow-up. The actual trial sample
size of 31 subjects per group was calculated to still provide .80%
power with a 2-sided a of 0.05. Preliminary blinded review of the
primary outcome data identified highly variable and nonnormally
distributed baseline respiratory event rates. The statistical analysis
plan of the primary outcome was then revised to use the
proportional means model, which accommodates variability in the
event rates between subjects. This modified plan was reviewed and
accepted by the Clinical Trial Data and Safety Monitoring Board
and approved by the sponsor prior to the final analysis. Crude
estimates of group differences in the change in the annualized event
rate from baseline to year 1 and year 2 were analyzed by linear
mixed models. Further analysis of treatment group differences was
assessed using variations of the Cox Proportional Hazards
model.41,42 Additional analyses of treatment group differences
are described in the supplemental data, including a per-protocol
analysis of the subset of participants who completed the 2-year
study (n 5 56), as well as a responder analysis using stepwise
logistic regression in which the entire per-protocol cohort was
divided into 2 groups defined by improved (“responder” n 5 36) or
unimproved (“nonresponder” n 5 20) annualized event rate in the
treatment phase relative to baseline. Study group differences in
continuous measures at baseline were compared using indepen-
dent Student t tests, and differences in dichotomous categorical
measures at baseline were compared using the Fisher’s exact test.
Treatment group differences in adverse events of at least grade 2
severity were assessed with the x2 or Fisher’s exact test. Statistical
analyses were conducted using SAS version 9.3 (SAS Institute
Inc.). All tests were 2-sided, with statistical significance prespecified
at P , .05.
Results
Enrollment and follow-up
Between 13 December 2011 and 20 June 2013, 70 patients with
baseline respiratory events data consented to participate and were
assessed for eligibility. Of the 99 patients with baseline respiratory
events data, no significant differences were found between the 70
patients who enrolled in the trial and the 29 patients who declined
participation. Sixty-two participants (mean age 9.9 6 3.9 [SD] years,
32 females [52%], predominantly with homozygous HbS disease
[87%]) passed screening and were randomly assigned to monthly
high-dose (n 5 31) or standard-dose (n 5 31) vitamin D3. Overall,
90.7% of the scheduled respiratory event questionnaires were
completed. For the high-dose group, 96.5% of the expected person-
months on study was completed compared with 93.4% in the standard-
dose group. The study visit for the last participant was completed on
16 July 2015. Figure 2 shows the participant flow diagram.
Characteristics of trial participants
The baseline demographic, clinical, and laboratory characteristics of
the trial participants were well-balanced between the treatment
groups (Table 1). A majority of the participants (77%) had insufficient
or deficient vitamin D levels (25-OHD ,20 ng/mL),35,36 with overall
mean baseline 25-OHD of 14.3 ng/mL (median 14.6, range 5-28),
which was not significantly different between the groups (P 5 .48).
70 Assessed for eligibility
62 Randomized
8 Excluded
   4 Not meeting inclusion
      criteria
   3 Declined participation
   1 Other reason
31 Assigned to receive vitamin D3
     100,000 IU per month
     31 Received intervention as
          assigned
       0 Did not receive assigned 
          intervention
2 Lost to follow-up
   (2 moved out of area)
1 Discontinued intervention
   (consent withdrawal)
0 Lost to follow-up
3 Discontinued intervention
   (2 chronic transfusions,
    1 consent withdrawal)
31 Assigned to receive vitamin D3
     12,000 IU per month
     31 Received intervention as
          assigned
       0 Did not receive assigned
          intervention
31 Included in analysis
  0 Excluded from analysis
31 Included in analysis
  0 Excluded from analysis
Figure 2. ViDAS participant flow diagram.
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The mean annual baseline respiratory event rate was 4.1, which was
almost identical to our estimated 4 events per year used in the
sample size and power calculations.
Primary outcome: respiratory events
The annual rate of respiratory events, predominantly respiratory
infections, did not differ significantly between the groups receiving
monthly high-dose and standard-dose oral vitamin D3 (P5 .24), but
it decreased significantly during year 2 in both groups (P 5 .0005;
Figure 3). No significant difference was found between the study
groups using proportional hazards estimates, including with
adjustments for mean baseline event rates, mean baseline
interevent interval, both mean baseline event rates and interevent
interval, gender, age, and hydroxyurea therapy (supplemental
Table 1). A per-protocol analysis (supplemental Table 2) and
a responder analysis (supplemental Table 3) also showed no
significant difference between the groups. Analysis of health care
utilization (emergency department and hospitalization) and treat-
ment (antibiotic use, oxygen requirement and transfusion) did not
Table 1. Baseline characteristics of participants in the ViDAS trial (N 5 62)
Characteristics Vitamin D3 100 000 IU/mo (n 5 31) Vitamin D3 12 000 IU/mo (n 5 31) P*
Age, mean 6 SD, y 9.9 6 4.0 9.9 6 3.8 0.98
Female, n (%) 16 (52) 16 (52) 1.00
Sickle cell type, n (%) 0.84
SS 26 (84) 28 (90)
SC 3 (10) 2 (6)
Sb0 thalassemia 1 (3) 1 (3)
Sb1 thalassemia 1 (3) 0 (0)
Hydroxyurea, n (%) 18 (58) 17 (55) 1.00
History of ACS, n (%) 9 (29) 10 (32) 1.00
History of asthma, n (%) 14 (45) 13 (42) 1.00
Oxygen saturation, mean 6 SD, % 98.9 6 1.5 98.7 6 1.4 0.57
25-Hydroxyvitamin D, mean 6 SD, ng/mL 15.0 6 7.0 13.6 6 6.2 0.48
Dietary vitamin D, mean 6 SD, IU/d 166.1 6 124.2 228.6 6 162.5 0.10
Dietary calcium, mean 6 SD, mg/d 838.2 6 522.4 941.9 6 617.3 0.49
Sun exposure, mean 6 SD, h/wk 9.1 6 8.7 8.6 6 6.0 0.99
Baseline respiratory events, mean 6 SD
Duration, d 419 6 202.2 470.8 6 161.2 0.28
Number, per patient 4.9 6 3.3 4.7 6 3.2 0.88
Annualized number 4.3 6 2.2 3.9 6 2.3 0.47
Interevent interval, d 74.7 6 52.9 108.6 6 96.2 0.10
Pulmonary function test, mean 6 SD† (n 5 28) (n 5 30)
FVC, % predicted 85.5 6 14.7 90.2 6 12.7 0.19
FEV1, % predicted 80.4 6 12.5 84.9 6 12.6 0.18
FEV1/FVC ratio, % 84.0 6 7.8 83.3 6 8.4 0.75
FEF25-75, % predicted 69.8 6 26.0 68.8 6 24.6 0.90
RV/TLC ratio, % 26.9 6 6.4 25.1 6 7.2 0.38
DLCO, % predicted 68.0 6 14.5 72.3 6 16.8 0.40
FENO, ppb 19.3 6 14.3 16.9 6 11.6 0.50
MIP, cm H2O 69.1 6 27.0 59.9 6 23.0 0.25
MEP, cm H2O 66.3 6 18.6 66.3 6 23.7 1.00
Hand-grip strength, mean 6 SD, pounds force‡ n 5 25 n 5 27
Right hand 21.1 6 16.2 16.9 6 11.5 0.28
Left hand 19.9 6 16.8 16.0 6 11.1 0.34
Dominant hand 21.2 6 16.2 17.1 6 11.3 0.30
DLCO, diffusing capacity of the lung for CO; FEF25-75, forced expiratory flow at 25%-75% vital capacity; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; MEP,
maximum expiratory pressure; MIP, maximum inspiratory pressure; RV, residual lung volume; TLC, total lung capacity.
*Baseline group differences were assessed by independent Student t test for continuous variables and by Fisher’s exact test for categorical variables.
†Performed only by participants ages $5 years.
‡Performed only by participants ages $6 years.
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show significant differences between the groups over the 2-year
treatment period (supplemental Table 4).
Serum 25-hydroxyvitamin D concentrations
As shown in Figure 4, the overall mean 25-OHD concentration
during the 2-year treatment period was significantly higher in the
high-dose group (mean 36.1 ng/mL) versus the standard-dose
group (mean 19.1 ng/mL; P , .001). The 25-OHD concentra-
tions of groups receiving 12 000 and 100 000 IU/mo of vitamin
D3 did not differ statistically at baseline, but they plateaued
at different levels at 3-4 months. For the final 20 months of the
24-month study, the standard-dose group stabilized at a mean
concentration of 19.3 ng/mL, with 60% of the observations in the
insufficient range (25-OHD, 12-20 ng/mL)36 and 15% in the
deficient range (25-OHD ,12 ng/mL).36 The high-dose group
stabilized at a mean concentration of 37.0 ng/mL, with 98% in the
sufficient range.14
Pulmonary function tests and hand dynamometry
Improvement in forced vital capacity (FVC) and forced expiratory
volume in 1 second (FEV1) were observed over time from baseline
to year 2, without significant differences between the groups.
However, there were no changes in % predicted FVC and %
predicted FEV1 (Table 2). Neither treatment had a significant effect
on FENO. Similarly, no significant differences in hand-grip strength
were observed over time and between the 2 groups (Table 2).
Safety monitoring
A total of 291 adverse events was reported, including 55 serious
adverse events in 20 subjects, most of which were expected for
sickle cell disease; none were attributed to the study drug (Table 3).
There were 17 abnormal safety laboratory values; all were
determined to be clinically insignificant, without requiring the
withholding or discontinuation of study treatment.
Discussion
In children and adolescents with sickle cell disease who received
monthly bolus doses of oral vitamin D3 under observation for 2
years, the annual rates of respiratory events (respiratory infections,
asthma exacerbations, or ACS) decreased by .50% during the
second year of treatment, with similar reductions in the groups
treated with 100 000 IU/mo or with 12 000 IU/mo. The treatment
groups did not differ significantly with respect to pulmonary function
and hand-grip strength. Both doses were safe, with no significant
differences in adverse events.
This is the first randomized clinical trial to examine the potential
benefit of vitamin D for preventing respiratory complications in sickle
cell disease. We chose monthly dosing to allow for directly
observed administration and avoid nonadherence with daily dosing.
Treatment duration was sufficiently prolonged to allow for seasonal
variation. Our primary outcome measure was collected biweekly
using a validated questionnaire38 to adequately capture all re-
spiratory events and was verified by a review of medical records.
Because we could not include a placebo group, given the known
risks for skeletal harm with vitamin D deficiency,14,35-37 the
decrease in the annual rates of respiratory events during year 2
cannot be ascribed unequivocally to vitamin D supplementation.
Nonetheless, no significant differences in the mean weekly rates of
influenza-like illnesses in New York City during the baseline and
study years (2012-2015) were found by the New York State
Department of Health Influenza-like Illness Surveillance Network.43
Moreover, because recruitment for the trial extended over 18
months, overlap between study participants receiving supplemen-
tation during years 1 and 2 was considerable and would mitigate
the impact of epidemiologic trends in respiratory illnesses that may



































Figure 3. Annual rates of respiratory events by treatment group. Data are
shown in a Tukey box plot. The horizontal line in the box represents the median.
The bottom and top of the box indicate the first and third quartiles; the upper
whisker shows the largest value from the top of the box that is no further than 1.5
times the interquartile range (IQR), the lower whisker shows the smallest value from
the bottom of the box to within 1.5 times the IQR, and data beyond the ends of the
whiskers are displayed as points. The mean (♦; 6 standard error of the mean [SEM])
annual rates of respiratory events at baseline, intervention year 1, and intervention
year 2 were 3.91 6 0.35, 3.34 6 0.37, and 1.54 6 0.37 and 4.34 6 0.35, 4.28
6 0.36, and 1.49 6 0.37, respectively, for monthly standard-dose and high-dose
oral vitamin D3. The rates did not differ significantly between the groups (P 5 .24), but
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Figure 4. Mean serum 25-hydroxyvitamin D concentrations by treatment
group. The mean serum 25-OHD concentrations of the groups receiving standard-
dose (12 000 IU/mo) and high-dose (100 000 IU/mo) vitamin D3 did not differ
statistically at baseline and rose to plateau at different levels at 3-4 months; overall
mean concentration during the 2-year treatment period was significantly higher in
the high-dose group (36.1 ng/mL) compared with the standard-dose group
(19.1 ng/mL; P , .001). Error bars indicate SEM.
974 LEE et al 8 MAY 2018 x VOLUME 2, NUMBER 9
treatment of patients enrolled in months 1-6 of the trial coincided
with year-1 treatment of patients enrolled in months 12-18.
In this study, the effects of standard- and high-dose vitamin D on
respiratory events were statistically indistinguishable. The similarity
of the response to the monthly standard- and high-dose vitamin D
might be interpreted to suggest that monthly standard-dose vitamin
D meets the requirement for respiratory health. In the standard-dose
group, the estimated mean dietary vitamin D of 228.6 IU/d, together
with the monthly supplement providing ;400 IU/d, would meet the
current Estimated Average Requirement for vitamin D of 600 IU/d.14
Nonetheless, 25-OHD concentrations were at insufficient or
deficient levels for skeletal health in 75% of the standard-dose
group, whereas they were in the sufficient range in 98% of the high-
dose group. A recent Cochrane review of vitamin D supplementa-
tion for sickle cell disease has concluded that previous clinical
studies were not of sufficient quality to guide clinical practice.44 Our
result provides evidence that the current Estimated Average
Requirement for vitamin D of 600 IU/d for skeletal health is
inadequate for patients with sickle cell disease when administered
as a monthly dose. Although the monthly high-dose vitamin D
supplement in our study did raise 25-OHD concentrations into the
sufficient range, bolus administration may fail to provide some
extraskeletal benefits.29
The timing of the observed decreases in the annual rates of
respiratory events and the uniformity in the magnitudes of the
reductions with the standard- and high-dose treatments potentially
could be explained by the monthly bolus dosing schedule for vitamin
D used in the trial. Since the design of our study, evidence has
accumulated that circulating concentrations of vitamin D3, the
parent compound, rather than those of 25-OHD, may be vital
determinants of the anti-infective, immunomodulatory, and other
extraskeletal effects of supplementation.23,45-47 To be active,
supplemental vitamin D3 must undergo 2 hydroxylations, first to
25-OHD and then to the functional metabolite, 1,25(OH)2D, which
binds to the vitamin D receptor to function as a transcription factor
inducing vitamin D–responsive genes. For the principal endocrine
functions of vitamin D, bone mineralization, and calcium and
phosphate homeostasis, the first hydroxylation takes place using a
25-hydroxylase in the liver,17,18,48 producing 25-OHD that enters
the circulation. The second hydroxylation occurs in the kidney, using
the 1-a-hydroxylase CYP27B1 to yield 1,25(OH)2D.
17,19 By
contrast, for extraskeletal autocrine and paracrine activities, vitamin
D3, the parent compound, enters cells more easily than 25-OHD,
and both hydroxylations may take place intracellularly.45,46,49
CYP27B1 and 25-hydroxylases are widely expressed and the
vitamin D receptor is present in most, if not all, cells of the immune
system.19











FVC, % predicted n 5 28 n 5 30 0.52
Baseline 85.5 6 2.8 90.2 6 2.3
Treatment year 1 85.2 6 2.7 92.4 6 2.3
Treatment year 2 85.0 6 2.5 92.1 6 2.5
FEV1, % predicted n 5 28 n 5 30 0.81
Baseline 80.4 6 2.4 84.9 6 2.3
Treatment year 1 79.1 6 2.7 85.3 6 2.1
Treatment year 2 78.9 6 2.8 84.5 6 2.0
FEV1/FVC ratio, % n 5 28 n 5 30 0.95
Baseline 84.0 6 1.5 83.3 6 1.5
Treatment year 1 82.6 6 1.0 81.7 6 1.3
Treatment year 2 82.2 6 1.5 81.6 6 1.2
FEF25-75, % predicted n 5 28 n 5 30 0.87
Baseline 69.8 6 5.2 68.8 6 4.9
Treatment year 1 62.9 6 4.4 64.8 6 4.3
Treatment year 2 62.8 6 4.4 65.6 6 4.3
RV/TLC ratio, % n 5 23 n 5 20 0.96
Baseline 26.9 6 1.3 25.1 6 1.6
Treatment year 1 25.4 6 1.8 22.6 6 1.9
Treatment year 2 22.8 6 1.6 21.8 6 1.9
DLCO, % predicted n 5 20 n 5 19 0.69
Baseline 68.0 6 3.2 72.3 6 3.9
Treatment year 1 62.9 6 3.2 67.8 6 2.4
Treatment year 2 68.1 6 3.8 72.9 6 2.9
FENO, ppb n 5 28 n 5 30 0.54
Baseline 19.3 6 2.7 16.9 6 2.1
Treatment year 1 20.5 6 3.5 16.1 6 2.1
Treatment year 2 18.1 6 2.7 16.4 6 2.4
MIP, cm H2O n 5 23 n 5 19 1.00
Baseline 69.1 6 5.6 59.9 6 5.3
Treatment year 1 78.7 6 6.1 80.4 6 6.3
Treatment year 2 77.4 6 5.0 74.6 6 4.7
MEP, cm H2O n 5 23 n 5 19 0.70
Baseline 66.3 6 3.9 66.3 6 5.4
Treatment year 1 60.4 6 3.3 57.3 6 3.1
Treatment year 2 58.7 6 3.4 56.2 6 4.0
Hand-grip strength
Right hand, pounds force n 5 25 n 5 27 0.81
Baseline 21.2 6 3.2 16.9 6 2.2
Treatment year 1 20.6 6 3.0 16.6 6 2.4
Treatment year 2 23.8 6 4.1 17.4 6 2.9
Left hand, pounds force n 5 25 n 5 27 0.97
Baseline 19.9 6 3.4 16.0 6 2.1
Treatment year 1 19.0 6 3.4 13.6 6 2.4










Dominant hand, pounds force n 5 25 n 5 27 0.24
Baseline 21.2 6 3.2 17.1 6 2.2
Treatment year 1 20.8 6 3.0 17.3 6 2.4
Treatment year 2 23.8 6 4.1 18.1 6 3.1
All data are mean 6 SEM.
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With a single oral bolus dose (12 000 IU) of vitamin D3, the half-life
of 25-OHD is on the order of weeks, whereas that of vitamin D3 is
;1 day. With a single oral bolus dose (100 000 IU) of vitamin D3,
25-OHD remains elevated for .3 months, whereas vitamin D3
returns to near baseline in ,1 week.45,46,50,51 The repeated oral
bolus doses of vitamin D3 resulted in the plateaus in 25-OHD
shown in Figure 4. Although we did not measure vitamin D3
concentrations in our study, neither the standard- nor high-dose
treatment would produce sustained increases in circulating vitamin
D3, potentially explaining the uniformity of response to the 2
treatments. Vitamin D3 in blood seems to be in diffusional
equilibrium with vitamin D3 in adipose tissue.
45 With bolus
doses, vitamin D3 in excess of use will accumulate in fat and
gradually raise circulating vitamin D3 concentrations. A year of
treatment with bolus dosing was potentially needed to permit
sufficient amounts of vitamin D3 to circulate, accumulate within
cells of the immune system, and produce the observed
reductions in the rates of respiratory events. In shorter trials of
bolus oral doses of vitamin D3, insufficient durations of treatment
could explain the lack of effect on respiratory infections,29,52
perhaps in conjunction with other possible explanations for the
lack of a protective effect of bolus doses of vitamin D.53-57 A
study comparing the effects of daily vitamin D3 (3333 IU) with
monthly bolus vitamin D3 (100 000 IU) on respiratory complica-
tions, together with measurements of serum vitamin D3, could
test these hypotheses.
Our study had several limitations. As noted earlier, a placebo group
could not be included in the trial design because of the established
risks of inadequate mineralization of the skeleton associated with
vitamin D deficiency.14,35-37 The primary outcome of the trial, the annual
rate of respiratory events, relied upon parent/self-reported responses
to the respiratory questionnaire. Although episodes of asthma
exacerbations and ACSwere reliably verified by review of documented
medical and hospital visits, respiratory infections constituted 93% of
the respiratory events. The respiratory questionnaire had a high
sensitivity (88%) and specificity (77%) for the viral respiratory
pathogens examined,38 but parent/self-reported responses are subject
to misclassification and, potentially, unconscious response bias. When
the study was designed, we relied upon serum 25-OHD as the
indicator of vitamin D status and did not include measurement of the
parent compound vitamin D3. Our sample size provided power to
detect a difference between the study treatments .80%, whereas
the numbers needed to detect a difference in individual events, such
as asthma exacerbations or ACS, would be much larger. Finally,
because the majority of our patients were treated with hydroxyurea,
the prevalence of ACS was reduced.
Children with sickle cell disease typically have low vitamin D
status,30,31 heightened susceptibility to respiratory infections and
asthma, and a greatly increased vulnerability to potentially fatal
complications of respiratory illness. Our study results provide
evidence for a substantial protective effect of vitamin D against
sickle cell respiratory complications that was manifest only after a
year of bolus administration. Daily administration would produce
sustained increases in the concentration of circulating vitamin D3
and could potentially show a more rapid protective effect, as
well as differences in the response to standard- and high-dose
treatments.45,46 Further studies using daily administration of vitamin
D3 could provide a simple and low-cost intervention to help avert
serious respiratory complications in sickle cell disease.
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Table 3. Adverse events by treatment allocation
Adverse event High dose (n 5 31)* Standard dose (n 5 31)* Odds ratio† 95% CI P‡
Pain syndrome 16 (51.6) 16 (51.6) 1.00 (0.37-2.71) 1.00
Fever 7 (22.6) 4 (12.9) 1.97 (0.51-7.56) 0.51
Blood bilirubin increased 3 (9.7) 4 (12.9) 0.72 (0.15-3.58) 1.00
Anemia 2 (6.5) 4 (12.9) 0.47 (0.08-2.57) 0.68
Injury 3 (9.7) 2 (6.5) 1.55 (0.24-10.01) 1.00
Cholecystitis 2 (6.5) 2 (6.5) 1.00 (0.13-7.59) 1.00
Surgical procedure 2 (6.5) 1 (3.2) 2.07 (0.18-24.08) 1.00
Urinary tract infection 3 (9.7) 1 (3.2) 3.21 (0.32-32.74) 0.62
Viral syndrome 2 (6.5) 1 (3.2) 2.07 (0.18-24.08) 1.00
Constipation 4 (12.9) 0 (0.0) 10.31 (0.53-20.18) 0.12
The table summarizes the number of participants with adverse events that were at least grade 2 in severity and occurred in $3 participants during the 2-year treatment period.
CI, confidence interval.
*All data are n (%).
†Mantel-Haenszel odds ratio when all cells have $1 count; logit odds ratio when a 0 cell is present.
‡Fisher’s exact test.
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